Media Summary: This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
Agdd 2024 D2s10 2 Analysis - Detailed Analysis & Overview
This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation addressed safety concern thresholds for extractables and leachables in ANDA submissions and covered ...
Closing remarks from day two of the Advancing Generic Drug Development Conference delivered by Dr. Robert Lionberger. This presentation provided key principles for comparative This presentation discussed in silico methodologies for topical products applied to the skin, with particular focus on dermal ... The final Q&A discussion panel from day one of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ...
This presentation described content and format requirements for composition statements of drug products and explained what to ... This presentation described how ongoing research contributes to the evolution of Product-Specific Guidances (PSGs) for topical ... This presentation explained how the totality of evidence was used to support bioequivalence assessment for locally acting ... The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation described different long-acting injectable (LAI) products and recognized regulatory and scientific challenges for ... FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ...
This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... This presentation described critical considerations for formulation development when a test product fails to meet the "no significant ...
